Previous 10 | Next 10 |
Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday. The stock opened at $179.86, then climbed to a daily high of $202.90 in the first hour of trading. The stock has a 52-week low of $118.18 and a 52-week high of $368.50. The stock i...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips I hope you had a happy Thanksgiving! If turkey leftovers didn’t put you to sleep on Friday, watching the stock market should’ve helped you fall asleep quickly instead. The reality is trading volume around Th...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hema...
BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA ® (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy in treatment naive CLL. BRUKINSA had a favorable...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important intersection of mental health and cancer care to help improve health outcomes for...
Summary Surging sales for its two self-developed drugs fueled an 88% rise in BeiGene's third-quarter revenue, but over $100 million in foreign exchange losses caused its net loss to also widen. At a time when many of its peers are cash-starved, the company has plenty of money in i...
BRUKINSA now approved in Brazil for three indications BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in Brazil for the treatment of adult patients with Waldenström’s macroglobul...
BeiGene press release ( NASDAQ: BGNE ): Q3 GAAP EPADS of -$5.39 misses by $1.54 . Revenue of $387.63M (+87.8% Y/Y) beats by $10.18M . For further details see: BeiGene GAAP EPADS of -$5.39 misses by $1.54, revenue of $387.63M beats by $10.18M
Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing 136% globally versus the third quarter of 2021, led by growth in the U....
BeiGene (NASDAQ: BGNE) , is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers. A...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...